Objectives: To evaluate the prevalence, impact, and risk factors for pain among a cohort of human immunodeficiency virus (HIV)infected adults treated with combination antiretroviral therapy if indicated according to current guidelines.
B efore effective combination antiretroviral therapy (cART), the results of several studies suggested that severe, disabling pain affected 60% to 80% of people living with human immunodeficiency virus (HIV). [1] [2] [3] [4] [5] However, since the advent of cART, the prognosis of HIV has been dramatically transformed with reductions in opportunistic infections and malignancies and life expectancy has normalized. 6, 7 This transformed prognosis has resulted in a growing population of aging individuals with prevalent HIV taking long-term cART who experience high levels of medical and psychiatric comorbidity. 8 Therefore, the emphasis of HIV management has changed to focus increasingly on symptoms, quality of life, and prevention and management of comorbidities.
There is growing evidence that, despite cART, pain remains a common problem among HIV-infected patients. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Some, but not all, authors report prevalence rates very similar to those observed pre-cART. 15, 16, 19 Miaskowski et al 16 reported not only that pain was common but also that it was frequently "severe" (59% of those reporting pain) and Merlin et al 19 showed that the pain was associated with significantly increased risk of impairment of physical function. However, Cervia et al 15 reported lower pain intensity scores and more transient, rather than chronic, pain in 41 patients after treatment with cART. There is controversy also about the role of immunological function and viral activity in the etiology of pain. Pre-cART studies suggested that pain increased in prevalence and intensity with disease progression. 5, 23 However, the findings of later studies suggested that effective cART attenuated the effects of disease stage or viral activity, as defined by CD4 + count or HIV viral load, on pain. 15 In some studies, risk factors for pain have included: female sex, lower socioeconomic status and educational attainment, depression, and high rates of previous or recent use of illicit drugs. 16, 17 There is also inconsistency in the literature as to whether pain is a side effect of some of the antiretroviral therapies. 10, 13, 24, 25 Although a distal polyradiculopathy was closely linked with dideoxynucleosides in early cART regimens, 26 these are generally avoidable with more modern treatment combinations. Therefore, our objective was to investigate the prevalence and distribution of pain among a UK cohort of HIV-infected adults treated according to best practice guidance with cART. We set out to quantify the prevalence of pain in the post-cART era, measure its impact in terms of intensity, effects on activities of daily living and health care utilization, and explore demographic, lifestyle, and clinical risk factors for occurrence to elucidate possible strategies for prevention and treatment.
METHODS
The sampling frame for this study included all HIVinfected adults who attended a routine outpatient appointment at a Teaching Hospital Center for HIV Medicine in the United Kingdom, January to October 2007. Patients were eligible if they were: aged 18 years and older and willing and able to provide written, informed consent. Eligible patients were only approached once. Patients were offered the questionnaire to complete in a private space and a trained member of the research team was highlighted as available if any additional information or assistance was required. Permission was also sought to interrogate the confidential clinical database within the center to collect HIV-related data (date of diagnosis, route of transmission, severity and course of disease, viral load, CD4 count, cART). The study protocol was approved by the Brighton Local Research and Ethics Committee (Ref: 06/Q1907/50).
The questionnaire enquired about demography (age, sex, ethnicity), lifestyle (smoking, alcohol), and employment status. The questions about pain were those used in a number of surveys of the prevalence of regional 27 and widespread pain. [28] [29] [30] All participants were asked "during the past month, have you had any aches or pains which have lasted for one day or longer?" The principal risk factor analyses were based upon those reporting current pain in response to the questions: "do you have any such aches or pains today?" Pain intensity was self-rated on an 11-point visual analogue scale (VAS) for the intensity of pain during the past month. Functional impact of pain was measured on another 11-point VAS in response to the question "in the past month, how much has pain interfered with your daily activities," rated on a scale of 0 to 10, where 0 is "no interference" and 10 is "unable to carry out activities"? The site-specific prevalence rates presented here were obtained from a series of similarly structured questions which asked: "during the past 1 month, have you had any pain from your (neck; shoulder; elbow; wrist/hand; hip; knee; ankle/foot) lasting for at least 1 week"? The questionnaire also enquired about health care use in relation to pain in the past month.
Psychological health and well-being were measured using the vitality and mental health domains of the SF-36 instrument. 31 Each domain was scored according to the SF-36 algorithm for each individual and the scores were investigated in tertiles of the distribution in relation to the pain outcomes: lowest tertile "best" mental health (referent) and highest tertile "worst" mental health).
Analysis was carried out with the SAS version 9.1 statistical package. The age-specific and sex-specific prevalence of pain lasting for >1 week out of the past month at different sites (with 95% confidence intervals generated using the exact binomial distribution where the group size was small, or the Normal approximation where group sizes were larger), the frequency of health care use and selfcompleted score for interference of the pain with daily activities were explored. The primary endpoint for the analysis was the reporting of current pain. Initial descriptive analyses illustrated the prevalence of current pain in each patient subgroup; univariate comparisons of the prevalence of pain were performed using w 2 tests. Potential risk factors considered are described in Table 1 and include: Table 1 , but were subsequently included in analyses in their continuous form if appropriate; the CDC stages B and C were combined as "symptomatic" as the prevalence of pain appeared to be similar in these 2 groups. Subsequently, factors that were identified as being associated with current pain in these univariate analyses (P < 0.10) were included in multivariable logistic regression analyses to identify factors that were independently associated with the outcome; factors were dropped from this model if nonsignificant until a parsimonious model was reached. Current working status and SF-36 scores were excluded from these models as factors which were likely to be consequent from the pain rather than causes of it.
RESULTS
In total, 1539 patients were registered with the centre during the study period among whom 1050 patients attended Z1 outpatient clinic. Of these, 859 (81.8%) consented to participate. A comparison of the distributions of sex, age, years since HIV diagnosis, CDC stage, and exposure to cART, showed no significant differences between those who did and did not complete a questionnaire (data not shown).
In total, 775 men and 84 women, median age 42 years, completed the questionnaire. Most were white and had prolonged duration since HIV diagnosis (Table 1) . Most were currently receiving cART (76.5%) and 68% had undetectable viral loads.
Pain
In total, 62.8% of respondents reported that they had experienced pain lasting >1 day in the past month (Table 2) , of whom 63.3% reported pain on the day of the survey. Eighty percent indicated duration of pain >3 months and 23.6% that the pain was "all over the body." The median number of sites affected was 2, but the range was 0 to 20 separate anatomic sites in men and 0 to 25 in women. The age-specific and sex-specific prevalence of pain is summarized in Figure 1 . Pain frequency and location was similar among men and women and increased with age in both sexes. The most commonly affected sites were: axial (neck and back), shoulder, and foot/ankle ( Fig. 2 ).
Impact of Pain
The median duration of pain was 3 years (range, 1 to 51 y) ( Table 2 ). The median pain intensity score recorded was 5.0 for men and 6.0 for women (mean scores 5.1 and 5.9, respectively). When asked to score the impact of pain on daily activities, the median score was 4.0 for men and 5.3 for women (mean scores 4.3 for men and 5.3 for women, respectively). In total, 43.8% of those in pain reported that they had consulted in primary care because of their pain (41.7% of men and 59.7% of women). One hundred and ninety-four (22.6%) were taking analgesics most days; 70 (8.2%) had received injections of local corticosteroid; 110 (12.8%) had seen a rheumatologist; 102 (11.9%) had seen an orthopedic surgeon; and 76 (8.9%) had attended the Emergency Department to request treatment for the pain. Current pain was associated with not being in work (P = 0.0001, 29.8% of those working vs. 53.5% of those not working reported current pain), and was strongly associated with psychological distress as measured by the SF- 36 
Risk Factors for Pain
In descriptive analyses (Table 1) , current pain was more prevalent in older individuals, in those with an undetectable (r40 copies/mL) viral load, in those with a longer time since HIV diagnosis, in those with more advanced CDC status, in those who had ever received or were currently receiving cART, and in those on a protease inhibitor (PI)-based (vs. a non-PI-based) cART regimen and in those receiving nucleoside analogue reverse transcriptase inhibitors (NRTIs) (vs. those not receiving NRTIs). Table 3 (left-hand side) reports the unadjusted odds ratios and 95% confidence intervals for these associations. Associations were also seen with working status and the SF-36 mentality and physical functioning scales in univariate analyses (Table 1) although these factors were not included in subsequent multivariable analysis as they are likely to be the result, rather than the cause, of the pain. Of the covariates considered, increasing age (adjusted odds ratio per 5 y older 1.10 [95% confidence interval, 1.02-1.19], P = 0.02), and longer time since diagnosis (adjusted odds ratio per 5 y longer 1.17 [1.03-1.32], P = 0.02) were independent predictors of current pain. Current use of a PIbased (1.39 [1.01-1.91], P = 0.04) regimen also remained significantly associated with current pain.
Finally, we considered whether the associations between current pain and sex and time since HIV diagnosis differed in men and women through the inclusion of interaction terms between sex and these covariates in the final model. Neither interaction term was significant (age: P = 0.27; time since HIV diagnosis: P = 0.46), suggesting that there was no evidence that these associations differed between sexes.
DISCUSSION
This study confirms that the prevalence (in this case the 1-mo period prevalence) of pain is high in people living with HIV. The estimated prevalence rate of 63% is consistent with that reported in other studies in the cART era 14, 16 and the findings of a systematic review of pain studies carried out before and after cART. 22 We found higher rates than the 39% reported by Cervia et al 15 in their US study of 41 patients who completed pain scores before and after commencement of cART, but our study includes a larger population with a wide range of disease duration and longer term exposure to cART. In keeping with the findings of some researchers, 5, 16 women in the current study reported higher rates of prevalence of pain than men, throughout the age range and at all anatomic sites. One study has, however, reported the opposite. 18 It is possible that the current study included a population that was more similar to those studied in the 2 (USA-based) studies than to the rural population studied by Mphalele and colleagues in South Africa and the differences may possibly be explained by cultural or ethnic differences in occurrence or reporting of pain. Clearly, this will require additional research in other ethnic groups and countries.
The median rating for pain severity in the current study was 5.0 (2.0-9.0) (moderately severe), a rating consistent with the results of most studies which have included a measure of pain severity. 22 Moderate to severe intensity pain is recognized to have a significant impact on ability to function and quality of life. Our results bear out this association as respondents scored the interference of their pain in the past month with their daily activities a median of 4.0 (0-9.0). This score is strikingly similar to that obtained by Breitbart et al 5 who surveyed ambulatory HIV patients in the pre-cART era and asked a similar question. In 2012, Merlin et al 19 reported that pain in HIV patients week during the past month at each regional site with 95% confidence intervals was associated with a 10-fold greater risk of impaired physical function, even after adjusting for mood, age, and substance abuse. Our results further substantiate their conclusion that pain should be an important consideration in HIV primary care. Overall, 35.5% of those with pain reported taking analgesics most days. Inadequacy of pharmacological pain management has been reported in previous studies among HIV-infected patients. Using pain management indexes, other investigators have reported suboptimal effectiveness of pain management in the majority (66% to 100%) of respondents. 22 Although we did not include a pain management index in this study, we were able to explore the percentage of people reporting pain receiving no treatment for pain, a measure used by other researchers as a marker of inadequate pain management. We found that 64.5% of our respondents in pain were not taking analgesics most days, a rate similar to that observed by others (40% to 73%). 22 However, further exploration revealed that those taking analgesics most days rated their pain as more intense on a VAS and rated the interference of their pain with their daily activities as greater than those not taking analgesics most days. Our study design does not allow us to investigate whether patients have been prescribed analgesics and are choosing not to take them regularly perhaps because of toxicity or inefficacy, or because they believe their symptoms are insufficiently severe. Therefore, future research could usefully explore prescription and adherence with prescription of analgesia and the reasons for which patients do/do not take the medications regularly if we are to better understand how to manage pain in HIV.
In accord with the results of other studies, 17, 19, 21 we found that pain in HIV was strongly associated with psychological ill health (P < 0.0001). Merlin and colleagues 17, 19, 21 have demonstrated this in several studies and have also shown that there is a strong interaction between pain, mood, substance abuse, and lower socioeconomic status. They also showed that people in pain were more likely to miss clinical appointments but only if they were not substance abusers. 17 Failure to attend appointments has important implications for medication adherence and treatment success in HIV. Our survey did not allow characterization of socioeconomic status in great detail, but we found a much higher proportion of worklessness among those reporting pain than among those without pain (P < 0.0001) and recognize the significance of worklessness as a factor importantly associated with poverty and socioeconomic status.
One of our aims was to explore the impact of parameters of HIV infection on pain. We found that duration of diagnosis of HIV was associated with pain and, in univariate analyses only, symptomatic stage of infection and cART exposure were also associated. Other studies have explored these parameters and produced inconclusive findings: for example, although the results of 3 studies suggested higher prevalence of pain with more advanced stage of infection, 32-34 3 others found no such association. 5, 35, 36 Moreover, 2 studies 14,37 found a higher prevalence of pain among those with lower CD + counts and 1 showed more pain sites among those with lower CD + counts, 32 3 others failed to see associations with CD + counts. 5, 35, 38 We found no association with viral loads or CD4 + counts in this study, but recognize that we were only able to explore the effects of the most recent results and that associations may have been present with nadir counts, which were not available for these participants. Some, but not all, studies have implicated cART in pain. Breitbart et al 5 who studied patients commencing cART, reported beneficial effects of cART on pain, whereas Richardson et al 37 reported no difference in rates of pain. In the current study, PI use was associated with pain (P = 0.04) in univariate, but not multivariable models. In clinical trials of PIs among naive HIV-infected patients and noninfected patients as postexposure prophylaxis, symptoms of muscle pain and joint pain are relatively commonly (10% to 30% incidence) reported but usually described as "mild" and "self-limiting." 24, 39 Of interest, PIs have been implicated as a cause of pain in another study of female HIV patients. 37 Given that we had relatively fewer female participants, this study was not powered to investigate a sex effect further and more research would be needed. Notably, use of PIs was recently shown to be associated with increased risk of peripheral neuropathy. 40 It is possible that PIs have some effect on peripheral or central pain pathways, but more research into the long-term impact of PIs will be required. This study included specific questions about pain at different anatomic sites, which allowed comparison of pain at different regional sites with those obtained from UK and US general population surveys. 27, 41 Broadly, the rates of prevalence and distribution were similar among those with HIV to those found in the general population with the exception of the results at the foot/ankle where we found much higher rates of pain prevalence. We hypothesize that this may reflect the common occurrence of peripheral neuropathy among HIVinfected adults. Some of the burden of neuropathy was caused by the neurotoxicity of some NRTI, particularly stavudine, didanosine, and zalcitabine, however, other HIV factors have been implicated including older age, coinfection, coexistent diabetes mellitus, and TB therapy with isoniazid. A recent study found that 32.1% of 2141 patients starting cART had evidence of a peripheral neuropathy after 3 years of followup, 40 despite excellent levels of viral and immunological control. It has been shown that the majority of patients (50% to 90%) with HIV-associated sensory neuropathy experience pain, proportions that are greater than in other common types of peripheral neuropathy such as diabetes and that recognition and treatment of painful sensory neuropathy in HIV is frequently suboptimal. 42 Interestingly, people with more advanced HIV infection have been shown more likely to report pain with their neuropathy. 43, 44 This epidemiologic study does not allow investigation of the etiology of pain, but we hypothesize that much of the excess reporting of foot/ankle pain in this study might be related to underlying sensory neuropathy.
The findings of this study must be taken alongside several limitations. This was a cross-sectional study so that the associations reported were cross-sectional and do not allow speculation about cause or effect or direction of association. Although the response rates were excellent (82%), and comparison of some of the key characteristics between those who did/did not complete the questionnaire revealed no significant differences, we cannot rule out the possibility that those who chose to complete the questionnaire were those who considered themselves affected by painful symptoms and that the estimated prevalence rates reported are therefore relative overestimates. These results were found from our survey among a well-characterized cohort of HIV-infected adults attending 1 UK center for their HIV care. However, this cohort of patients may differ from those attending other HIV centers in the United Kingdom and elsewhere. For example, most of this cohort is male and white and most acquired HIV through sexual contact. We cannot exclude the possibility that there are factors peculiar to this cohort that also affect pain that are not generalizable to patients infected with the virus through different modes of transmission or from different ethnicities. For example, we showed no statistically significant association between mode of transmission of HIV and pain in the current study but other investigators found that mode of transmission was important and, in particular, that intravenous drug use was associated with higher pain levels and pain at a higher mean number of sites. 32, 35 Our cohort only included 8 patients known to have been infected by intravenous drug use so that this study was underpowered to detect this association. Similar studies will need to be carried out in different HIV cohorts to see if our findings are generalizable.
Our results suggest that duration of HIV diagnosis is importantly associated with pain and this may reflect a number of factors: immunological function and viral activity; increasing burden of physical and psychological comorbidities; increasing numbers of non-HIV medications; and reduced resilience to side effects. Current immunological function and viral activity were investigated using the most recent CD4 + cell count and viral load for each patient and showed no important relationships with pain. However, it may well be that disease status might be more usefully represented by nadir CD4 + count, as a marker of disease state at its worst, rather than recent count and it is a limitation of this study that these data were not available for this cohort of patients. Further research will be needed to clarify the role of disease stage and viral activity on pain in cART-treated patients. This study was also not designed to collect information about non-HIV morbidities or medications used for other diseases so we are also unable to investigate the role of those factors.
In summary, we have reported the results of a large-scale epidemiological survey of the occurrence of pain in HIVinfected adults and found that it is a very common symptom associated with substantial morbidity and that feet/ankles are more commonly affected than in other populations. Crosssectionally, the risk factors were age and time since diagnosis of HIV. Current use of PIs may be associated with pain but further research is warranted.
